In vivo delivery of a multiepitope peptide and Nef protein using novel cell-penetrating peptides for development of HIV-1 vaccine candidate

Biotechnol Lett. 2021 Mar;43(3):547-559. doi: 10.1007/s10529-020-03060-3. Epub 2021 Jan 1.

Abstract

Objectives: A potent HIV vaccine should overcome some limitations such as polymorphism of human HLA, the diversity of HIV-1 virus, and the lack of an effective delivery system. In this study, a DNA construct encoding Nef60-84, Nef126-144, Vpr34-47, Vpr60-75, Gp16030-53, Gp160308-323, and P248-151 epitopes was designed using bioinformatics tools. The pcDNA3.1-nef-vpr-gp160-p24 and pcDNA3.1-nef constructs were prepared in large scale as endotoxin-free form. Moreover, the recombinant Nef-Vpr-Gp160-p24 polypeptide and Nef protein were generated inE. coli. These constructs were delivered using cell penetrating peptides (CPPs) in vivo, and immune responses were assessed for different modalities in BALB/c mice.

Results: The recombinant DNA constructs were confirmed as the ~ 867 bp and ~ 648 bp bands related tonef-vpr-gp160-p24 andnef genes on agarose gel. Moreover, the purified Nef-Vpr-Gp160-p24 polypeptide and Nef protein showed the ~ 32 kDa and ~ 30 kDa bands on SDS-PAGE, respectively. The results of immune responses indicated that the heterologous prime/boost regimens using both Nef-Vpr-Gp160-P24 and Nef antigens induced significantly the secretion of IgG2a, IgG2b, IFN-γ and Granzyme B compared to other groups. The levels of Granzyme B in mice immunized with Nef antigen were higher than those immunized with Nef-Vpr-Gp160-P24 antigen. The CPPs showed the same potency with Montanide adjuvant for eliciting immune responses.

Conclusions: The heterologous prime/boost regimens for both antigens could significantly direct immune responses toward Th1 and CTL activity compared to other regimens. Comparing the efficiency of Nef-Vpr-Gp160-P24 and Nef constructs, the Nef-Vpr-Gp160-P24 constructs delivered by CPPs showed promising results as an HIV vaccine candidate.

Keywords: Adjuvant; Cell-penetrating peptide; HIV-1; Nef; Polyepitope vaccine; Prime-boost strategy.

MeSH terms

  • AIDS Vaccines* / chemistry
  • AIDS Vaccines* / genetics
  • AIDS Vaccines* / immunology
  • Adjuvants, Immunologic
  • Animals
  • Cell-Penetrating Peptides* / chemistry
  • Cell-Penetrating Peptides* / genetics
  • Cell-Penetrating Peptides* / immunology
  • Drug Delivery Systems / methods*
  • Epitopes* / chemistry
  • Epitopes* / genetics
  • Epitopes* / immunology
  • Female
  • HIV Antibodies / immunology
  • HIV-1 / genetics
  • HIV-1 / immunology
  • Mice
  • Mice, Inbred BALB C
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • nef Gene Products, Human Immunodeficiency Virus* / chemistry
  • nef Gene Products, Human Immunodeficiency Virus* / genetics
  • nef Gene Products, Human Immunodeficiency Virus* / immunology

Substances

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Cell-Penetrating Peptides
  • Epitopes
  • HIV Antibodies
  • Recombinant Fusion Proteins
  • nef Gene Products, Human Immunodeficiency Virus
  • nef protein, Human immunodeficiency virus 1